Aethlon Medical, Inc. (NASDAQ:AEMD) Short Interest Update

Aethlon Medical, Inc. (NASDAQ:AEMD) was the recipient of a significant drop in short interest in the month of June. As of June 15th, there was short interest totaling 187,291 shares, a drop of 43.3% from the May 31st total of 330,345 shares. Based on an average trading volume of 370,446 shares, the short-interest ratio is presently 0.5 days. Currently, 8.0% of the company’s stock are sold short.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Aethlon Medical in a report on Monday, April 20th. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Reduce”.

Institutional Trading of Aethlon Medical

An institutional investor recently bought a new position in Aethlon Medical stock. Citadel Advisors LLC acquired a new stake in Aethlon Medical, Inc. (NASDAQ:AEMD) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 95,084 shares of the medical equipment provider’s stock, valued at approximately $71,000. Citadel Advisors LLC owned 36.57% of Aethlon Medical at the end of the most recent reporting period. 1.99% of the stock is owned by institutional investors and hedge funds.

Aethlon Medical Trading Down 7.9%

NASDAQ AEMD traded down $0.07 during trading hours on Wednesday, hitting $0.76. The company’s stock had a trading volume of 230,190 shares, compared to its average volume of 339,800. The company has a market capitalization of $1.80 million, a PE ratio of -0.05 and a beta of 1.49. The company’s 50-day simple moving average is $2.03 and its two-hundred day simple moving average is $2.25. Aethlon Medical has a 52 week low of $0.65 and a 52 week high of $27.40.

Aethlon Medical Company Profile

Aethlon Medical, Inc (NASDAQ: AEMD) is a clinical‐stage biotechnology company focused on developing novel immunotherapeutic medical devices to address life‐threatening diseases. The company’s lead product candidate, the Hemopurifier®, is an extracorporeal affinity device designed to remove circulating viruses and immunosuppressive exosomes from the bloodstream. By targeting glycosylated pathogens and exosomes, Aethlon aims to restore immune function and improve patient outcomes in oncology and infectious disease settings.

The Hemopurifier platform leverages proprietary lectin affinity technology to selectively bind and eliminate harmful particles without depleting healthy blood components.